Catherine Broome, MD, Georgetown University Hospital, Washington, DC, discusses the promise of targeting the complement cascade in warm and cold autoimmune hemolytic anemias (AIHAs). An FDA-approved treatment already exists for patients with cold agglutinin disease (CAD), targeting the classical complement pathway, which is responsible for the hemolysis observed in these patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
